{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-021834","form_type":"8-K","ticker":"FATE","cik":"0001434316","company_name":"FATE THERAPEUTICS INC","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.640959+00:00","generated_at":"2026-06-22T08:39:28.764144+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Fate Therapeutics Q3 2022: Cash $519M, $15M revenue; FDA positive feedback on FT516 RMAT; pipeline progress","bullets":["Cash and investments $519.1M; Q3 revenue $15.0M from Janssen/ONO collaborations; R&D expense $79.8M.","Positive FDA feedback under FT516 RMAT for clonal master iPSC bank and potential registrational study design; CMC meeting set for December.","Enrollment ongoing for FT596+R three-dose escalation at 1.8B cells/dose for R/R BCL; activating community sites for FT596+R-CHOP in newly-diagnosed aggressive BCL.","Janssen exercised option for second iPSC-derived CAR NK product targeting undisclosed hematologic malignancy antigen; FT555 (GPRC5D) IND candidate for MM to be presented at ASH.","14 abstracts selected for ASH and 12 for SITC, including interim Phase 1 data for FT576 (MM), FT819 (BCL), FT536/FT538 (solid tumors)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-021834","json":"https://secwatch.observer/filing/0000950170-22-021834.json","markdown":"https://secwatch.observer/filing/0000950170-22-021834.md","text":"https://secwatch.observer/filing/0000950170-22-021834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022021834/0000950170-22-021834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022021834/fate-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:39:28.764144+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d85e4d55d73d5485d180994e4b01a456d26a03b","claim":"FATE THERAPEUTICS INC reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 3, 2022, Fate Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434316/000095017022021834/0000950170-22-021834-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}